Earnings Outlook For Relmada Therapeutics
Portfolio Pulse from Benzinga Insights
Relmada Therapeutics (NASDAQ:RLMD) is scheduled to release its quarterly earnings report on March 19, 2024, with an expected EPS of $-0.83. Historical data shows mixed reactions to past earnings, with a notable 132.23% stock increase over the last 52 weeks. Investors are advised to watch for the company's guidance for future growth.
March 18, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Relmada Therapeutics is expected to report an EPS of $-0.83 for the upcoming quarter. Historical performance shows mixed reactions to earnings announcements, but the stock has seen significant growth over the past year.
The expected EPS of $-0.83 sets a cautious tone, but historical data indicates that RLMD's stock price does not always directly correlate with earnings performance. The significant year-over-year stock growth suggests underlying investor confidence, which may buffer any negative impact from the earnings report. However, the guidance provided by the company will be crucial in determining short-term stock movement.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100